Search - tctmd.com

Displaying 161 - 180 of 478

Sort: Relevancy | Date

Presentation TCT 2017

TCT 10: Mechanisms of Very Late Bioresorbable Scaffold Thrombosis Assessed by Optical Coherence Tomography - Insights From the International INVEST Registry

Presenter: Yoshinobu Onuma, Joanna J. Wykrzykowska, Lorenz Raber

October 31, 2017

Presentation TCT 2017

RECOVERY: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating vs a Polymer-Free Metallic DES in Patients With Coronary Artery Disease

Presenter: David P. Faxon, Joseph A. Hill, Ling Tao

October 31, 2017

Presentation TCT 2017

Association Between Scaffold Under-Expansion and Late Lumen Loss After Bioresorbable Scaffold Implantation - IVUS and Angiographic Insights From the ABSORB Japan Trial

Presenter: Yoshinobu Onuma, Joanna J. Wykrzykowska, Kozo Okada, MD

October 31, 2017

Presentation TCT 2017

ABSORB II: 4-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Presenter: Robert-Jan van Geuns, Bernard R. Chevalier

October 31, 2017

Presentation TCT 2017

ABSORB 3-Year Meta-analysis: 3-Year Outcomes of a Bioresorbable Scaffold Compared to a Metallic DES From an Individual Patient Data Meta-analysis of Four Randomized Trials

Presenter: David P. Faxon, Joseph A. Hill, Ziad A. Ali

October 31, 2017

Presentation TCT 2017

ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Stephen G. Ellis

October 31, 2017

Presentation TCT 2017

Maximizing Long-term Outcome: DES, DCB, and Combination Therapies

Presenter: Mahmood K. Razavi, Peter A. Schneider, George L Adams

October 31, 2017

Presentation TCT 2017

DCB Preclinical Perspectives: Mechanisms and Experimental Safety and Efficacy of Older, Current, and Futuristic DCB

Presenter: Robert A. Byrne, Ran Kornowski, Juan F. Granada

October 30, 2017

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

$Treatment of Refractory In-Stent Restenosis State-of-the-Art Review: From Standard Approaches to Parental Drugs and Vascular Brachytherapy$

Presentation TCT 2017

Treatment of Refractory In-Stent Restenosis State-of-the-Art Review: From Standard Approaches to Parental Drugs and Vascular Brachytherapy

Presenter: Robert A. Byrne, Ran Kornowski, Ron Waksman

October 30, 2017

Presentation TCT 2017

Debate: Drug Coated Balloons Will Eventually Show Benefit for Infrapopliteal Arteries - Con!

Presenter: Subhash Banerjee, Robert A. Lookstein

October 30, 2017

News Conference News TCT 2017

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Todd Neale

October 30, 2017

Presentation TCT 2017

Treatment of First-time In-Stent Restenosis State-of-the-Art Review: From Lesion Preparation and Imaging to Restenting to DCB

Presenter: Robert A. Byrne, Ran Kornowski, Fernando Alfonso

October 30, 2017

Presentation TCT 2017

Debate: Drug Coated Balloons Will Eventually Show Benefit for Infrapopliteal Arteries - Pro!

Presenter: Subhash Banerjee, Bryan T. Fisher

October 30, 2017

Presentation TCT 2017

Is There a Role for Sidebranch Treatment With Drug-Eluting Balloons?

Presenter: Antonio Colombo, Manuel Pan, Jozica Sikic

October 30, 2017

Presentation TCT 2017

Does DCB Technology Have an Important Role in Treatment of De Novo Coronary Artery Disease? If Not Today, Tomorrow?

Presenter: Robert A. Byrne, Ran Kornowski, Bernardo Cortese

October 30, 2017

Presentation TCT 2017

Drug-Coated Coronary Balloon Therapy: Current State-of-the-Art

Presenter: Robert A. Byrne, Ran Kornowski, Bruno Scheller

October 30, 2017

Presentation TCT 2017

PLLA-Based Biolimus A9 Elution II: From Nobori to Ultimaster Specifications and Results

Presenter: Ioannis Iakovou, Gert Richardt, Shigeru Saito

October 30, 2017

Presentation TCT 2017

Drug Coated Balloons in Complex SFA Lesions: Case Examples and Data

Presenter: Subhash Banerjee

October 30, 2017

Advertisement

TCT 10: Mechanisms of Very Late Bioresorbable Scaffold Thrombosis Assessed by Optical Coherence Tomography - Insights From the International INVEST Registry

RECOVERY: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES With a Luminal CD34+ Antibody Coating vs a Polymer-Free Metallic DES in Patients With Coronary Artery Disease

Association Between Scaffold Under-Expansion and Late Lumen Loss After Bioresorbable Scaffold Implantation - IVUS and Angiographic Insights From the ABSORB Japan Trial

ABSORB II: 4-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

ABSORB 3-Year Meta-analysis: 3-Year Outcomes of a Bioresorbable Scaffold Compared to a Metallic DES From an Individual Patient Data Meta-analysis of Four Randomized Trials

ABSORB IV: 30-Day Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Maximizing Long-term Outcome: DES, DCB, and Combination Therapies

DCB Preclinical Perspectives: Mechanisms and Experimental Safety and Efficacy of Older, Current, and Futuristic DCB

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Treatment of Refractory In-Stent Restenosis State-of-the-Art Review: From Standard Approaches to Parental Drugs and Vascular Brachytherapy

Debate: Drug Coated Balloons Will Eventually Show Benefit for Infrapopliteal Arteries - Con!

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Treatment of First-time In-Stent Restenosis State-of-the-Art Review: From Lesion Preparation and Imaging to Restenting to DCB

Debate: Drug Coated Balloons Will Eventually Show Benefit for Infrapopliteal Arteries - Pro!

Is There a Role for Sidebranch Treatment With Drug-Eluting Balloons?

Does DCB Technology Have an Important Role in Treatment of De Novo Coronary Artery Disease? If Not Today, Tomorrow?

Drug-Coated Coronary Balloon Therapy: Current State-of-the-Art

PLLA-Based Biolimus A9 Elution II: From Nobori to Ultimaster Specifications and Results

Drug Coated Balloons in Complex SFA Lesions: Case Examples and Data

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content